-
Monday, 03/27/2023
Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
On February 14th, 2023, an article was published in the journal Critical Care titled "Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia". This study, conducted by an international team of researchers led by Dr. Antoni Torres, focuses on the treatment of pneumonia caused by Pseudmonas aeruginosa.
Pneumonia is a serious respiratory illness that can be caused by several bacteria, including Pseudomonas aeruginosa, which is known for its resistance to conventional antibiotics. Intravenous antibiotics often achieve suboptimal pulmonary concentrations, which can reduce their effectiveness. Therefore, the aim of this study was to evaluate the effect of inhaled amikacin (AMK) combined with intravenous meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia.
The study's results demonstrated that the use of inhaled AMK in combination with intravenous MEM was not effective in reducing the bacterial burden in the lungs nor in preventing the dissemination of infection compared to the use of intravenous MEM alone. However, inhaled AMK improved bacterial eradication in the proximal airways and hindered antibiotic resistance. This suggests that inhaled AMK could be a promising treatment for prevention pneumonia caused by Pseudomonas aeruginosa.
Dr. Torres, the lead author of the study, commented: "This study is an important step in the search for effective treatments for pneumonia, especially in cases of antibiotic-resistant bacteria. We hope that these results will lead to further clinical studies and ultimately more effective treatments for patients with pneumonia."
This study was funded by the Carlos III Health Institute and the European Regional Development Fund. The full article is available in the journal Critical Care (https://doi.org/10.1186/s13054-023-04331-x ).